Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

被引:18
|
作者
Xu, Xi [1 ,2 ]
Ren, Jie [1 ,2 ]
Ma, Yinghe [1 ,2 ]
Liu, Hongting [1 ]
Rong, Quanjin [1 ]
Feng, Yifan [1 ]
Wang, Yameng [1 ]
Cheng, Yu [1 ]
Ge, Ruijia [3 ]
Li, Zhiyu [1 ,2 ]
Bian, Jinlei [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing, Jiangsu, Peoples R China
[3] Madeira Sch, Mclean, VA USA
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
Indoleamine 2,3-dioxygenase 1; inhibitor; virtual screen; cyanopyridine scaffold; hit optimisation; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; CRYSTAL-STRUCTURES; POTENT INHIBITORS; MOLECULAR DOCKING; DETAILED ANALYSIS; DENDRITIC CELLS; DERIVATIVES; DESIGN; EXPRESSION;
D O I
10.1080/14756366.2018.1480614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
引用
收藏
页码:250 / 263
页数:14
相关论文
共 50 条
  • [1] Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening
    Zhou, Yeheng
    Peng, Jiale
    Li, Penghua
    Du, Haibo
    Li, Yaping
    Li, Yingying
    Zhang, Li
    Sun, Wei
    Liu, Xingyong
    Zuo, Zhili
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2019, 78 : 306 - 316
  • [2] Discovery of novel and potent inhibitors of indoleamine-2,3-dioxygenase (IDO1) for cancer immunotherapy
    Liu, Shengyang
    Tao, Taoliangshan
    Liang, Yue
    Guo, Hongli
    Ye, Xiaogang
    Wu, Zhiheng
    Bao, Fang
    Yang, Heping
    Cai, Yaxian
    Yang, Gangjing
    Wang, Longsheng
    Liu, Fang
    Fu, Guangliang
    Liu, Xiaolei
    Du, Jiangang
    Qin, Ping
    Ma, Yuanfei
    Zhu, Panhu
    Yu, Yajun
    Ma, Chen
    Wang, Pei
    Zhao, Liping
    Wang, Yuxun
    Gao, Daxin
    Li, Qun
    CANCER RESEARCH, 2016, 76
  • [3] Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors
    Singh, Rahul
    Salunke, Deepak B.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [4] Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Roehrig, Ute F.
    Majjigapu, Somi Reddy
    Vogel, Pierre
    Zoete, Vincent
    Michiein, Olivier
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (24) : 9421 - 9437
  • [5] Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
    Zhang, Hongjun
    Liu, Kun
    Pu, Qinglin
    Achab, Abdelghani
    Ardolino, Michael J.
    Cheng, Mangeng
    Deng, Yongqi
    Doty, Amy C.
    Ferguson, Heidi
    Fradera, Xavier
    Knemeyer, Ian
    Kurukulasuriya, Ravi
    Lam, Yu-hong
    Lesburg, Charles A.
    Martinot, Theodore A.
    McGowan, Meredeth A.
    Miller, J. Richard
    Otte, Karin
    Biju, Purakattle J.
    Sciammetta, Nunzio
    Solban, Nicolas
    Yu, Wensheng
    Zhou, Hua
    Wang, Xiao
    Bennett, David Jonathan
    Han, Yongxin
    ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (11): : 1530 - 1536
  • [6] Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Wang, Xiu-Xiu
    Sun, Si-Yu
    Dong, Qing-Qing
    Wu, Xiao-Xiang
    Tang, Wei
    Xing, Ya-Qun
    MEDCHEMCOMM, 2019, 10 (10) : 1740 - 1754
  • [7] Potent and selective next generation inhibitors of indoleamine-2,3-dioxygenase (IDO1) for the treatment of cancer
    Powers, Jay P.
    Walters, Matthew J.
    Noubade, Rajkumar
    Young, Stephen W.
    Marshall, Lisa
    Melom, Jan
    Park, Adam
    Shah, Nick
    Bjork, Pia
    Fridman, Jordan S.
    Beck, Hilary P.
    Chian, David
    McKinnell, Jenny V.
    Osipov, Maksim
    Reilly, Maureen K.
    Shunatona, Hunter P.
    Walker, James R.
    Zibinsky, Mikhail
    Jaen, Juan C.
    CANCER RESEARCH, 2015, 75
  • [8] Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
    Sari, Suat
    Tomek, Petr
    Leung, Euphemia
    Reynisson, Johannes
    MOLECULES, 2019, 24 (23):
  • [9] Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors
    Gao, Dingding
    Li, Yingxia
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (14) : 3780 - 3791
  • [10] A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Xu, Haojie
    Song, Yunlong
    Yang, Qing
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2017, 65 (08) : 714 - 717